SPECIAL NOTICE
A -- PHASE 3 EFFICACY TESTING OF THE AD26.MOS4.HIV + GP140 PROTEINS HIV VACCINE
- Notice Date
- 3/6/2019
- Notice Type
- Synopsis
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Attn: MCMR-AAA 820 Chandler Street Frederick, MD 21702-5014 MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-19-SSN-JD4-01
- Response Due
- 3/20/2019
- Point of Contact
- Jamie Diggs, Contract Specialist, Phone 3016192663
- E-Mail Address
-
jamie.l.diggs.civ@mail.mil
- Small Business Set-Aside
- N/A
- Description
- The Government intends to award a sole source contract to Janssen Vaccines and Prevention B.V. (Janssen). This sole source is due to the fact that Janssen hold the Investigation New Drug application for the Ad26.Mos4.HIV + gp140 protein HIV vaccine, and is the regulatory sponsor of all of the clinical studies (Phase 1 and 2) conducted to date. Janssen will conduct a Phase 3 efficacy study, which is required to obtain FDA licensure. NOTE: THIS NOTICE WAS NOT POSTED TO FEDBIZOPPS ON THE DATE INDICATED IN THE NOTICE ITSELF (06-MAR-2019); HOWEVER, IT DID APPEAR IN THE FEDBIZOPPS FTP FEED ON THIS DATE. PLEASE CONTACT 877-472-3779 or fbo.support@gsa.gov REGARDING THIS ISSUE.
- Web Link
-
Link To Document
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-19-SSN-JD4-01/listing.html)
- Record
- SN05241592-F 20190308/190306230029 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |